Zenith Capital (TSXV:ZENI.P) EPS (Diluted) : C$-0.15 (TTM As of Jan. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital EPS (Diluted)?

Zenith Capital's Earnings per Share (Diluted) for the three months ended in Jan. 2024 was C$-0.03. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.15.

Zenith Capital's EPS (Basic) for the three months ended in Jan. 2024 was C$-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.15.

Zenith Capital's EPS without NRI for the three months ended in Jan. 2024 was C$-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.15.

During the past 3 years, the average EPS without NRIGrowth Rate was -5.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 54.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Zenith Capital's highest 3-Year average EPS without NRI Growth Rate was 71.50% per year. The lowest was -5.10% per year. And the median was 71.50% per year.

Zenith Capital EPS (Diluted) Historical Data

The historical data trend for Zenith Capital's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital EPS (Diluted) Chart

Zenith Capital Annual Data

Trend

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

EPS (Diluted)

Get a 7-Day Free Trial

-3.37

-0.10

-0.06

-0.08

-0.12

Zenith Capital Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EPS (Diluted)	Get a 7-Day Free Trial															-0.01	-0.07	-0.03	-0.03	-0.03

Competitive Comparison of Zenith Capital's EPS (Diluted)

For the Biotechnology subindustry, Zenith Capital's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's PE Ratio distribution charts can be found below:

* The bar in red indicates where Zenith Capital's PE Ratio falls into.

Zenith Capital EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Zenith Capital's Diluted EPS for the fiscal year that ended in Apr. 2023 is calculated as

Diluted EPS (A: Apr. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-17.691	-	0)	/	138.843
	=	-0.13

Zenith Capital's Diluted EPS for the quarter that ended in Jan. 2024 is calculated as

Diluted EPS (Q: Jan. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-3.279	-	0)	/	152.319
	=	-0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.15

Zenith Capital (TSXV:ZENI.P) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Zenith Capital EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Zenith Capital's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (TSXV:ZENI.P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corporation (TSXV:ZENI.P) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2475 Queens Avenue, West Vancouver, BC, CAN, V7V 2Y9

Website

https://www.zenithepigenetics.com

Zenith Capital Corporation is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical needs. The company is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaborators; triple-negative breast cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator; androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator.

Zenith Capital (TSXV:ZENI.P) Headlines

No Headlines